<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Evidence suggests that insulin-like growth factor 2 messenger <z:chebi fb="40" ids="33697">RNA</z:chebi> binding protein 3 (IGF2BP3, also known as IMP3) represents a promising <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> biomarker </plain></SENT>
<SENT sid="1" pm="."><plain>However, the clinical, pathological, molecular and prognostic features of IGF2BP3-positive <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> remain uncertain </plain></SENT>
<SENT sid="2" pm="."><plain>MATERIALS AND METHODS: We evaluated IGF2BP3 expression by immunohistochemistry in 671 rectal and <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cases that form part of a molecular pathological epidemiology database </plain></SENT>
<SENT sid="3" pm="."><plain>Cox proportional hazards regression models were used to compute mortality hazard ratio (HR), adjusting for clinical, pathological and molecular features, including microsatellite instability, the CpG island methylator phenotype, LINE-1 methylation and KRAS, BRAF and PIK3CA mutations </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Among 671 colorectal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, 234 (35%) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> were positive for IGF2BP3 </plain></SENT>
<SENT sid="5" pm="."><plain>In contrast, <z:mpath ids='MPATH_458'>normal</z:mpath> colorectal epithelium was negative for IGF2BP3 in <z:hpo ids='HP_0000001'>all</z:hpo> 403 specimens of <z:mpath ids='MPATH_458'>normal</z:mpath> mucosa adjacent to <z:mp ids='MP_0002038'>carcinoma</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>IGF2BP3 positivity was associated with poor differentiation (p=0.0003), stage III-IV disease (p=0.0081), BRAF mutation (p=0.031), and LINE-1 hypomethylation (p=0.020) </plain></SENT>
<SENT sid="7" pm="."><plain>IGF2BP3 positivity was significantly associated with shorter <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>-specific [log-rank p&lt;0.0001; multivariate HR, 1.37; 95% confidence interval (CI), 1.02-1.84] and overall survival (log-rank p=0.0004; multivariate HR, 1.32; 95% CI, 1.05-1.66) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: IGF2BP3 expression in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> is associated with adverse clinical outcome </plain></SENT>
<SENT sid="9" pm="."><plain>Our findings support a role for IGF2BP3 as a diagnostic and/or prognostic biomarker in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>